Drugs that contain Topiramate

1. List of Eprontia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(17 years from now)

Market Authorisation Date: 05 November, 2021

Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; Indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

How can I launch a generic of EPRONTIA before it's patent expiration?
More Information on Dosage

2. List of Qudexy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(10 years from now)

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QUDEXY XR before it's patent expiration?
More Information on Dosage

3. List of Trokendi Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889191 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8298580 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8877248 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9555004 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US10314790 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9622983 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US9549940 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8663683 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8992989 SUPERNUS PHARMS Sustained-release formulations of topiramate
Nov, 2027

(4 years from now)

US8298576 SUPERNUS PHARMS Sustained-release formulations of topiramate
Apr, 2028

(5 years from now)

Market Authorisation Date: 16 August, 2013

Treatment: Treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine; Use of trokendi xr for the treatment of epilepsy

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of TROKENDI XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic